Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled phase 1 and phase 2 trials to assess the safety, tolerability and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fan-Yue, Gao, Fan, Jia, Si-Yue, Wu, Xiang-Hong, Li, Jing-Xin, Guo, Xi-Ling, Zhang, Jia-Lu, Cui, Bo-Pei, Wu, Zhi-Ming, Wei, Ming-Wei, Ma, Zhi-Long, Peng, Hai-Lin, Pan, Hong-Xing, Fan, Lin, Zhang, Jing, Wan, Jiu-Qin, Zhu, Zhong-Kui, Wang, Xue-Wen, Zhu, Feng-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281021/
https://www.ncbi.nlm.nih.gov/pubmed/34267185
http://dx.doi.org/10.1038/s41392-021-00692-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281021/
https://www.ncbi.nlm.nih.gov/pubmed/34267185
http://dx.doi.org/10.1038/s41392-021-00692-3

Ejemplares similares